Efficacy and safety of platelet-rich plasma therapy in systemic sclerosis and localized scleroderma; a systematic review
Archives of Dermatological Research · 27.02.2025 · 317 (1)
DOI: 10.1007/s00403-025-03934-4 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Archives of Dermatological Research, online erschienen am 27.02.2025. Verfasst von Mohammad Ali Nilforoushzadeh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Skin Repair Research Center, Jordan Dermatology and Hair Transplantation Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Platelet-Rich Plasma, Scleroderma, Systemic, Scleroderma, Localized. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Abstract (Originalsprache)
Systemic sclerosis (SSc) and localized scleroderma (LoSc) are rare connective tissue diseases that are identified by skin thickening and hardening with different mechanisms of action. Although advancements in treatments have been achieved in recent years, these conditions remain a major cause of morbidity and currently lack a definitive cure. We sought to evaluate the efficacy and safety of platelet-rich plasma (PRP) treatment in individuals with LoSc and SSc. PubMed/Medline, Ovid-Embase, and Web of Science were systematically searched until December 27th, 2024. A citation search was also carried out, and clinical studies published in English were eligible to be included. A total of 11 studies utilized PRP to treat different conditions of scleroderma. In limited and diffuse forms of SSc, PRP resulted in the improvement of mouth handicap in systemic sclerosis (MHISS) items, skin elasticity, skin ulcer healing, and vascularization both alone and alongside hyaluronic acid, autologous fat, and stromal vascular fraction. Moreover, PRP injections led to a significant decrease in the LoSc cutaneous assessment tool (LoSCAT), as well as a reduction in pain and disease symptoms. Furthermore, patients with en coupe de sabre experienced hair regrowth after PRP treatment. The adverse effects, which can be limited or diffuse, were mild and self-limited. PRP contains a considerable number of platelets, cytokines, and growth factors. PRP is considered a safe supplementary treatment option alongside standard therapy for both LoSc and SSc, with the potential to promote improvement in these patients, either as a standalone therapy or in conjunction with other therapeutic approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Skin Repair Research Center, Jordan Dermatology and Hair Transplantation Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, 1449614535, Iran.
- Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
- School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
- School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Skin Repair Research Center, Jordan Dermatology and Hair Transplantation Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. niloofar.nobari@yahoo.com.
Zitieren
APA
Nilforoushzadeh, M. A., Heidari, A., Ghane, Y., Hosseini, S., Azizi, H., Najar Nobari, N., & Heidari, N. (2025). Efficacy and safety of platelet-rich plasma therapy in systemic sclerosis and localized scleroderma; a systematic review. Archives of Dermatological Research, 317(1). https://doi.org/10.1007/s00403-025-03934-4
Vancouver
Nilforoushzadeh MA, Heidari A, Ghane Y, Hosseini S, Azizi H, Najar Nobari N, et al. Efficacy and safety of platelet-rich plasma therapy in systemic sclerosis and localized scleroderma; a systematic review. Archives of Dermatological Research. 2025;317(1). doi:10.1007/s00403-025-03934-4
BibTeX
@article{Nilforoushzadeh2025,
author = {Nilforoushzadeh, Mohammad Ali and Heidari, Amirhossein and Ghane, Yekta and Hosseini, Seyedayin and Azizi, Hanieh and Najar Nobari, Niloufar and Heidari, Nazila},
title = {Efficacy and safety of platelet-rich plasma therapy in systemic sclerosis and localized scleroderma; a systematic review},
journal = {Archives of Dermatological Research},
year = {2025},
volume = {317},
number = {1},
doi = {10.1007/s00403-025-03934-4}
}
EUVIMED